Interstitial lung disease
Conditions
Interventions
1:Dextromethorphan+Pirfenidone
2:Pirfenidone
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patients who met the IPF diagnostic criteria of ATS / ERS / JRS / ALAT in 2018: HRCT accorded with UIP type and possible UIP type; 2. Patients aged 18 to 75 years; 3. Those patients who fully understand the treatment purpose and grouping method, and those who may have adverse reactions such as gastrointestinal discomfort, liver dysfunction, skin damage and so on, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with allergy or intolerance to pirfenidone and dextromethorphan; 2. Patients who had used glucocorticoid or immunosuppressant within one month before enrollment; 3. Patients who have been used for a long time (>=2 weeks) with fibrogenic drugs such as amiodarone; 4. Patients with typical CTD-ILD.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest HRCT;Pulmonary Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood routine, Liver Function,Renal Function; | — |
Countries
China
Contacts
Public ContactJing Feng
Tianjin Medical University General Hospital
Outcome results
None listed